Tepmetko is a prescription drug approved for adults with metastatic non-small cell lung cancer (NSCLC) that carries a specific alteration called MET exon 14 skipping. This targeted treatment works differently from traditional chemotherapy by focusing on a driver mutation that fuels cancer growth. Here, we will explore how Tepmetko works, who may be eligible, and what the tepmetko prescribing information says about its use.

How Tepmetko Works as a Targeted Therapy

Tepmetko belongs to a class of medicines called kinase inhibitors. It specifically blocks the activity of a protein known as MET that is abnormally active in some lung cancers due to MET exon 14 skipping alterations. By inhibiting this signaling pathway, the tepmetko drug can help slow or stop the growth of cancer cells. According to the FDA, Tepmetko is approved for adults with metastatic NSCLC with MET exon 14 skipping alterations. The American Cancer Society notes that targeted therapies like this one have transformed treatment for people with specific genetic changes in their tumors. Your doctor will test your tumor tissue or blood for this alteration before considering Tepmetko.

Who May Benefit from Tepmetko Treatment

Tepmetko is intended for a specific group of patients, not all lung cancer cases. You may be a candidate if you have been diagnosed with advanced or metastatic non-small cell lung cancer and your tumor tests positive for the MET exon 14 skipping mutation. This genetic alteration is found in a small percentage of lung cancers, making testing a crucial first step. Here are key eligibility considerations based on the tepmetko prescribing information:

  • You must have metastatic NSCLC, meaning the cancer has spread to other parts of the body.
  • Your tumor must show MET exon 14 skipping alterations confirmed by an FDA-approved test.
  • You may have received prior treatment or be newly diagnosed, as Tepmetko can be used in either setting depending on your doctor's judgment.
  • Your overall health and organ function must be suitable for therapy, as determined by your oncologist.

Discussing your specific diagnosis with your healthcare team is essential before starting treatment.

Key Points from Tepmetko Prescribing Information

The tepmetko prescribing information provides detailed guidance on how this medication is given and what to expect. Tepmetko is taken by mouth as a tablet, typically once daily, with or without food. Your doctor may adjust the dose based on how you tolerate the treatment. The manufacturer states that patients should have regular blood tests to monitor liver function and other health markers during treatment. Because Tepmetko can affect the liver, your healthcare provider will check these values before starting and periodically while you are taking the tepmetko drug. The FDA emphasizes that you should not stop or change the dose without talking to your doctor first. Always read the medication guide provided with your prescription.

Talking to Your Doctor About Tepmetko

If you or a loved one has advanced lung cancer, asking about biomarker testing is an important first step. You might say, 'Have I been tested for MET exon 14 skipping?' If that alteration is present, Tepmetko could be an option to discuss. Your oncologist can review the tepmetko prescribing information with you and explain whether this treatment fits your situation. Keep a list of questions to ask, including how the drug is taken, what monitoring is needed, and what signs should prompt a call to your care team. The American Cancer Society recommends open communication with your cancer care team to make the best treatment decisions. Remember, this article is for educational purposes and does not replace professional medical advice. Consult your doctor for personalized guidance.

Why Tepmetko Matters Tepmetko is a targeted option for advanced lung cancer with a specific genetic change. Understanding the tepmetko prescribing information and discussing it with your doctor can help you make an informed decision. If you are facing this diagnosis, consider asking about biomarker testing and whether Tepmetko might be right for you. Learning more today can empower your next conversation with your care team.